about
Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trialLauric acid-rich medium-chain triglycerides can substitute for other oils in cooking applications and may have limited pathogenicityShift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventionsWhole Blood Gene Expression Profiling in Preclinical and Clinical Cattle Infected with Atypical Bovine Spongiform EncephalopathyNutritional Aspects of Treatment in Epileptic PatientsAlternate day fasting impacts the brain insulin-signaling pathway of young adult male C57BL/6 miceSimultaneous detection of cerebral metabolism of different substrates by in vivo ¹³C isotopomer MRS.Pharmacogenetic analysis of the effects of polymorphisms in APOE, IDE and IL1B on a ketone body based therapeutic on cognition in mild to moderate Alzheimer's disease; a randomized, double-blind, placebo-controlled study.Role of Medium Chain Triglycerides (Axona®) in the Treatment of Mild to Moderate Alzheimer's Disease.Vascular and metabolic dysfunction in Alzheimer's disease: a review.D-beta-hydroxybutyrate extends lifespan in C. elegans.Ketone body utilization drives tumor growth and metastasis.Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.Global cPILOT analysis of the APP/PS-1 mouse liver proteome.Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Ketone bodies and two-compartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells.Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer's disease: a prospective, open-label pilot studyHyperketonemia and ketosis increase the risk of complications in type 1 diabetes.Can Ketones Help Rescue Brain Fuel Supply in Later Life? Implications for Cognitive Health during Aging and the Treatment of Alzheimer's DiseaseRetrospective case studies of the efficacy of caprylic triglyceride in mild-to-moderate Alzheimer's disease.Hitting a moving target: Basic mechanisms of recovery from acquired developmental brain injury.The energy-redox axis in aging and age-related neurodegeneration.The Population Pharmacokinetics of D-β-hydroxybutyrate Following Administration of (R)-3-Hydroxybutyl (R)-3-Hydroxybutyrate.Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease.Dietary therapies for epilepsy: future research.Can ketones compensate for deteriorating brain glucose uptake during aging? Implications for the risk and treatment of Alzheimer's disease.Neuroketotherapeutics: A modern review of a century-old therapy.Integration between Glycolysis and Glutamate-Glutamine Cycle Flux May Explain Preferential Glycolytic Increase during Brain Activation, Requiring Glutamate.The efficacy of the ketogenic diet on motor functions in Parkinson's disease: A rat modelA ketogenic diet improves motor performance but does not affect β-amyloid levels in a mouse model of Alzheimer's disease.Is on-admission capillary blood beta-hydroxybutyrate concentration associated with the acute stroke severity and short-term functional outcome?Intermittent Fasting Alleviates the Increase of Lipoprotein Lipase Expression in Brain of a Mouse Model of Alzheimer's Disease: Possibly Mediated by β-hydroxybutyrate.Additional mechanisms for brain activation failure due to reduced glucose metabolism-a commentary on Zilberter and Zilberter: The vicious circle of hypometabolism in neurodegenerative diseases.Dietary energy substrates reverse early neuronal hyperactivity in a mouse model of Alzheimer's disease.Mild experimental ketosis increases brain uptake of 11C-acetoacetate and 18F-fluorodeoxyglucose: a dual-tracer PET imaging study in rats.Potential Synergies of β-Hydroxybutyrate and Butyrate on the Modulation of Metabolism, Inflammation, Cognition, and General Health.Microbiome-metabolome signatures in mice genetically prone to develop dementia, fed a normal or fatty diet.Treatment of Prurigo Pigmentosa with Diet Modification: A Medical Case Study.
P2860
Q21245063-FFE68050-AB36-4087-B41F-D23BA70CE464Q26740087-40B17DF9-F87F-47B6-B955-B7540FEC7DFCQ26830740-10F710F2-C145-4CB9-AE10-AB1829DB0A7BQ27314189-D850D700-161E-46DF-8385-B9C239DC9CC0Q28079443-6563912A-556D-4D8A-8CB6-CC510FA3DADBQ28386794-4F5C77FC-B694-43C0-9664-25C55AA74D68Q30467587-F7E94C3B-B329-4111-A4D8-258E2D5CA388Q31033689-E15CB187-7E44-4243-8A43-F1A3941DC0D8Q33460503-2AE4BB22-EE13-4EF7-B7BB-41E04770DFEFQ34193337-F59A790E-1DFB-42A0-B7CA-977FE4D72751Q34217599-1892234D-9AE1-48EC-8ED5-85196E6095DAQ34307146-BE8F6CCE-AAC3-4202-A34C-F025F564AEBAQ34407220-52707E29-B50E-4894-9135-7C52090A4D95Q34459615-47E8E717-C880-4992-A59C-19B661BEF8FEQ35958359-ED5DE0AD-3FC6-41DC-B190-8DFA3CE28F11Q36426491-F2D76342-4FFE-44A8-9E8B-25E87C8345A4Q36462966-EFD3B564-0418-40F2-9D7B-E6FDD5C481F8Q36901925-3AFEBFBA-B110-480B-A9C5-50187616A720Q37075513-11F87CC2-2C53-46E1-A1FA-30704EC97AE0Q37260956-EFF3E79B-7081-4D8E-ABAC-B7F4B1F7752AQ37409435-76D8A9D1-A428-4D28-870F-3C370A631012Q37588978-0025FDE4-6790-4EBE-94AC-D3AF0FC9DF0CQ37600359-071F0C74-4F1B-4A67-B192-1E866B1ABEA2Q37675866-CBCD9D38-BC23-48A2-92B3-B9467313F867Q37858251-E3F49226-E94D-4F44-B3BA-64E45133576DQ38696404-5C526F41-7B98-477E-9BEE-EE7F3E975A7CQ38745984-277020AC-AF57-4B1A-879F-8D3FA5B124BCQ41547542-0AF79236-12F3-446B-84BA-C885C48AEC7EQ41853478-2F97A45A-23E4-4CE4-BC1B-6C2AD9B3624AQ42910540-B67E6CC9-5CB6-4C17-A349-580FBB771302Q45802219-2589D5FB-6D22-4FE8-A1BF-7B4D2AA41C9BQ47827819-DB402EC7-BFA8-4270-9F3F-418919A6F1E5Q47990556-00BA6595-C5A1-4838-A688-8D09F37E6ECFQ48253009-6AE10E8F-21EB-4F19-8984-856AEEE0F494Q51372979-0A1D9EE6-163E-43AF-B8BD-F49B08693650Q55114436-374F9AD3-CE01-4AA1-B12C-4ED76686056DQ55192874-7CBBFC25-95FA-4609-9434-51B4825E426DQ55257318-D185ADC8-3C10-4EC2-824A-F54723895955
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Ketone bodies as a therapeutic for Alzheimer's disease.
@ast
Ketone bodies as a therapeutic for Alzheimer's disease.
@en
Ketone bodies as a therapeutic for Alzheimer's disease.
@nl
type
label
Ketone bodies as a therapeutic for Alzheimer's disease.
@ast
Ketone bodies as a therapeutic for Alzheimer's disease.
@en
Ketone bodies as a therapeutic for Alzheimer's disease.
@nl
prefLabel
Ketone bodies as a therapeutic for Alzheimer's disease.
@ast
Ketone bodies as a therapeutic for Alzheimer's disease.
@en
Ketone bodies as a therapeutic for Alzheimer's disease.
@nl
P2860
P1433
P1476
Ketone bodies as a therapeutic for Alzheimer's disease.
@en
P2093
Samuel T Henderson
P2860
P2888
P304
P356
10.1016/J.NURT.2008.05.004
P577
2008-07-01T00:00:00Z
P5875
P6179
1034523119